FLOT Plus Durvalumab Leads to High pCR Rate in Gastric Cancer - Physician's Weekly

Stomach or gastric cancer with organs and tumors or cancerous cells 3D rendering illustration. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts. stock photo

FLOT Plus Durvalumab Leads to High pCR Rate in Gastric Cancer

Durvalumab + 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a higher pathological complete response (pCR) rate than FLOT alone.